Impact Biomedical (IBO) Profit After Tax (2022 - 2026)

Impact Biomedical (IBO) has 5 years of Profit After Tax data on file, last reported at -$2.3 million in Q1 2026.

• Quarterly Profit After Tax fell 78.95% year-over-year to -$2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.4 million (up 22.55% YoY) and the FY2024 annual result came in at -$24.7 million, down 460.65% from the prior year.
• Profit After Tax fell to -$2.3 million in Q1 2026, from -$1.5 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $4.2 million in Q3 2024 to a low of -$27.1 million in Q4 2024.
• A 5-year average of -$3.7 million and a median of -$1.3 million in 2023 frame the typical range for Profit After Tax.
• The widest YoY moves for Profit After Tax: up 460.83% in 2024, down 2049.72% in 2024.
• Tracing IBO's Profit After Tax over 5 years: stood at -$3.4 million in 2022, then jumped by 62.54% to -$1.3 million in 2023, then plunged by 2049.72% to -$27.1 million in 2024, then soared by 94.58% to -$1.5 million in 2025, then plunged by 55.58% to -$2.3 million in 2026.
• The last three Profit After Tax figures came in at -$2.3 million (Q1 2026), -$1.5 million (Q3 2025), and -$14.3 million (Q2 2025), per Business Quant data.